A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea

Takeda

Status: Enrolling

Conditions: Colorectal Cancer

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT07035886

TAK-113-4001

Details and patient eligibility

About

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to (>=)18 years.
• Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
• Participant voluntarily consent to participate in the study.

Exclusion criteria

• Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
• Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
• Pregnant or breastfeeding women.

Trial design

600 participants in 1 patient group

All Study Participants

Description:

Data will be collected for participants with metastatic colorectal cancer (mCRC) who will receive Fruzaqla according to the approved indication as per the Physician's routine schedule.

Treatment:

Other: No intervention